TransMedics Group, Inc. (NASDAQ:TMDX) Receives Consensus Recommendation of “Hold” from Brokerages

TransMedics Group, Inc. (NASDAQ:TMDX) has earned a consensus rating of “Hold” from the thirteen brokerages that are covering the company, MarketBeat reports. Seven equities research analysts have rated the stock with a hold rating and six have issued a buy rating on the company. The average 12-month price objective among brokerages that have issued a report on the stock in the last year is $134.00.

Several equities analysts have issued reports on the stock. Wall Street Zen lowered shares of TransMedics Group from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. Stifel Nicolaus decreased their target price on shares of TransMedics Group from $85.00 to $75.00 and set a “hold” rating for the company in a research report on Tuesday, May 26th. Needham & Company LLC decreased their target price on shares of TransMedics Group from $174.00 to $142.00 and set a “buy” rating for the company in a research report on Wednesday, May 6th. JPMorgan Chase & Co. lifted their price objective on shares of TransMedics Group from $114.00 to $149.00 and gave the company a “neutral” rating in a report on Wednesday, February 25th. Finally, Piper Sandler cut their price objective on shares of TransMedics Group from $160.00 to $120.00 and set an “overweight” rating for the company in a report on Wednesday, May 6th.

Institutional Trading of TransMedics Group

A number of institutional investors and hedge funds have recently modified their holdings of TMDX. Royal Bank of Canada boosted its holdings in TransMedics Group by 47.9% in the 1st quarter. Royal Bank of Canada now owns 26,582 shares of the company’s stock worth $1,788,000 after buying an additional 8,604 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in TransMedics Group by 4.7% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 19,525 shares of the company’s stock worth $1,314,000 after buying an additional 868 shares during the last quarter. Goldman Sachs Group Inc. boosted its holdings in TransMedics Group by 20.6% in the 1st quarter. Goldman Sachs Group Inc. now owns 507,510 shares of the company’s stock worth $34,145,000 after buying an additional 86,721 shares during the last quarter. Russell Investments Group Ltd. boosted its holdings in TransMedics Group by 13.5% in the 2nd quarter. Russell Investments Group Ltd. now owns 7,901 shares of the company’s stock worth $1,059,000 after buying an additional 938 shares during the last quarter. Finally, M&T Bank Corp acquired a new stake in TransMedics Group in the 2nd quarter worth about $209,000. Hedge funds and other institutional investors own 99.67% of the company’s stock.

TransMedics Group Price Performance

NASDAQ TMDX opened at $71.14 on Tuesday. The firm’s fifty day simple moving average is $88.16 and its two-hundred day simple moving average is $116.65. The company has a current ratio of 6.74, a quick ratio of 6.19 and a debt-to-equity ratio of 1.70. TransMedics Group has a 12-month low of $60.10 and a 12-month high of $156.00. The firm has a market capitalization of $2.46 billion, a P/E ratio of 16.17 and a beta of 1.92.

TransMedics Group (NASDAQ:TMDX) last released its quarterly earnings results on Tuesday, May 5th. The company reported $0.30 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.62 by ($0.32). TransMedics Group had a return on equity of 22.38% and a net margin of 27.04%.The firm had revenue of $173.93 million during the quarter, compared to analysts’ expectations of $174.44 million. During the same period in the prior year, the firm posted $0.70 earnings per share. TransMedics Group’s revenue for the quarter was up 21.2% compared to the same quarter last year. Analysts forecast that TransMedics Group will post 1.98 EPS for the current fiscal year.

About TransMedics Group

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.